We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Share
  • Facebook
  • Twitter
  • Linked In
  • Google+
back top
Newsletter 2022 Autumn Edition

1300 members from 70 countries Join ICRS

News

The ICRS Newsletter Autumn 2022 Issue is now out of press. Hard copies will be delivered to our members and partners worldwide in the next 3 weeks. Enjoy Reading…

Newsletter 2022 Autumn Edition

Newsletter 2022 Autumn Edition

18/10/2022

Vericel (Nasdaq: VCEL), a specialty biologics company with three approved cellular therapy products on the market might still be underappreciated by investors after its recent run?

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

01/09/2017